A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
← catalyst calendarNCT06926621 · readout in 894 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
44estimated
Sites
15
Countries
Australia, Belgium, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-28 | actual | When the study began enrolling |
| Primary completion | 2029-01-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myotonic Dystrophy Type 1 (DM1)
Intervention
- Drug: VX-670
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From Day 1 up to Week 108
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed